Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06685133 · ClinicalTrials.gov registry record

Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice

A clinical trial of Lung Cancer and Lung Nodule, sponsored by Noah Medical.

Active
Registry status
50
Enrollment target
2
Study locations

NCT06685133 is a study of Lung Cancer and Lung Nodule that is active but no longer recruiting, run by Noah Medical. The registered enrollment target is 50 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06685133, a study of Lung Cancer and Lung Nodule, is active but no longer recruiting, sponsored by Noah Medical.

ACTIVE NOT RECRUITING
Registry status
50 participants
Enrollment target
2
Study locations

Study Summary

A prospective observational study evaluating the accuracy of the tool-in-lesion technology of the Galaxy SystemTM in normal clinical practice.

Conditions Studied

Interventions

  • DEVICE Robotic assisted bronchoscopy

Study Locations (2)

Tennessee

  • CHI Memorial Hospital - Chattanooga

Virginia

  • Inova Fairfax Medical Campus - Falls Church

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-11-08
Est. Completion 2027-10-30

Sponsor

Noah Medical

1 total trials

What the Registry Record Tells You About NCT06685133

The ClinicalTrials.gov registry entry for NCT06685133 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Noah Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Robotic assisted bronchoscopy is the first listed.

NCT06685133 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Virginia.

Frequently Asked Questions

What is clinical trial NCT06685133 about?

NCT06685133 is a clinical study titled "Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice". A prospective observational study evaluating the accuracy of the tool-in-lesion technology of the Galaxy SystemTM in normal clinical practice.

What is the current status of trial NCT06685133?

This trial is currently active not recruiting. The enrollment target is 50 participants. The study started on 2024-11-08. Estimated completion is 2027-10-30.

What conditions does trial NCT06685133 study?

This clinical trial studies the following conditions: Lung Cancer, Lung Nodule.

What interventions are being tested in trial NCT06685133?

The interventions under investigation include: Robotic assisted bronchoscopy (DEVICE).

Who is sponsoring clinical trial NCT06685133?

This trial is sponsored by Noah Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06685133 being conducted?

This trial has 2 study locations across Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.